Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526966 | 1.00 | CHRM2 (0.57) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL12004666 | 1.00 | CHRM2 (0.57) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL25134189 | 0.96 | CHRM2 (0.54) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL10316948 | 0.90 | MEN1 (0.53) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL25180666 | 0.90 | MEN1 (0.53) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL15982318 | 0.90 | ALDH1A1 (0.49) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL25422192 | 0.90 | ALDH1A1 (0.49) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL2811174 | 0.90 | ALDH1A1 (0.49) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL12004770 | 0.90 | ALDH1A1 (0.49) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL28519312 | 0.90 | ALDH1A1 (0.49) | CHRM2CHRM4CHRM1CHRM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181847-A1 | Targeted Imaging and/or Therapy Using the Staudinger Ligation | BTD, HLCS, BOLA2; BOLA2B | CHRM2 4796/4885CHRM4 4644/4885CHRM1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.